Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6215716 | 0.99 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2AURKARPS6KB1AURKB | |
| SCHEMBL6216578 | 0.97 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2AURKARPS6KB1AURKB | |
| SCHEMBL6215445 | 0.95 | CHRM4 (0.41) | ALDH1A1SMN1; SMN2AURKARPS6KB1AURKB | |
| SCHEMBL6213497 | 0.94 | CHRM4 (0.41) | ALDH1A1SMN1; SMN2AURKARPS6KB1AURKB | |
| SCHEMBL6215426 | 0.93 | AURKA (0.45) | ALDH1A1SMN1; SMN2AURKARPS6KB1AURKB | |
| SCHEMBL6763971 | 0.92 | CHRM4 (0.42) | ALDH1A1SMN1; SMN2AURKARPS6KB1AURKB | |
| SCHEMBL6235752 | 0.91 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL6238548 | 0.90 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL6217080 | 0.88 | CHRM4 (0.43) | ALDH1A1SMN1; SMN2AURKARPS6KB1AURKB | |
| SCHEMBL6763501 | 0.88 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1084125-B1 | CONDENSED THIENOPYRIMIDINES WITH PHOSPHODIESTERASE-V INHIBITING ACTION | MERCK PATENT GMBH (DE) | 2005-12-28 | — | — | EP | claimed |
| EP-1259229-B1 | USE OF BENZO-THIENO[2,3-d]PYRIMIDINES HAVING PDE V INHIBITING ACTIVITY FOR THE TREATMENT OF ERECTILE DYSFUNCTION | MERCK PATENT GMBH (DE) | 2005-06-15 | — | — | EP | claimed |
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | MERCK PATENT GMBH (DE) | 2004-04-22 | — | — | US | claimed |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | claimed |
| US-20040058940-A1 | Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) | MERCK PATENT GMBH (DE) | 2004-03-25 | — | — | US | claimed |
| EP-1347762-A2 | PHARMACEUTICAL FORMULATION CONTAINING THIENOPYRIMIDINES AND ANTITHROMBOTICS, CALCIUM ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES (2) | MERCK PATENT GmbH (DE) | 2003-10-01 | — | — | EP | claimed |
| US-20030022906-A1 | Use of pde v inhibitors | MERCK PATENT GMBH (DE) | 2003-01-30 | — | — | US | claimed |
| US-6495557-B1 | SUCH AS 3-(4-(3-CHLORO-4-METHOXYBENZYLAMINO)BENZO-(4,5)-THIENO (2,3-D)PYRIMIDIN-2-YL)PROPIONIC ACID; CARDIOVASCULAR DISORDERS AND/OR IMPAIRED POTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-12-17 | — | — | US | claimed |
| EP-1259229-A2 | USE OF PDE V INHIBITORS | MERCK PATENT GmbH (DE) | 2002-11-27 | — | — | EP | claimed |
| WO-2002049649-A2 | PHARMACEUTICAL FORMULATION CONTAINING THIENOPYRIMIDINES AND ANTITHROMBOTICS, CALCIUM ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES (2) | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | claimed |
| EP-1212062-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 2002-06-12 | — | — | EP | claimed |
| WO-2001064192-A2 | USE OF BENZOTHIENO-2,3-D-PYRIMIDINES WITH PDE V INHIBITORY EFFECT FOR THE TREATMENT OF ERECTILE DYSFUNCTION | MERCK PATENT GMBH (DE) | 2001-09-07 | — | — | WO | claimed |
| WO-2001019369-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 2001-03-22 | — | — | WO | claimed |
| EP-1084125-A1 | CONDENSED THIENOPYRIMIDINES WITH PHOSPHODIESTERASE-V INHIBITING ACTION | MERCK PATENT GmbH (DE) | 2001-03-21 | — | — | EP | claimed |
| WO-1999055708-A1 | CONDENSED THIENOPYRIMIDINES WITH PHOSPHODIESTERASE-V INHIBITING ACTION | MERCK PATENT GMBH (DE) | 1999-11-04 | — | — | WO | claimed |
| EP-1084125-B1 | CONDENSED THIENOPYRIMIDINES WITH PHOSPHODIESTERASE-V INHIBITING ACTION | MERCK PATENT GMBH (DE) | 2005-12-28 | — | — | EP | disclosed |
| EP-1259229-B1 | USE OF BENZO-THIENO[2,3-d]PYRIMIDINES HAVING PDE V INHIBITING ACTIVITY FOR THE TREATMENT OF ERECTILE DYSFUNCTION | MERCK PATENT GMBH (DE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2002049649-A2 | PHARMACEUTICAL FORMULATION CONTAINING THIENOPYRIMIDINES AND ANTITHROMBOTICS, CALCIUM ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES (2) | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | disclosed |
| EP-1084125-A1 | CONDENSED THIENOPYRIMIDINES WITH PHOSPHODIESTERASE-V INHIBITING ACTION | MERCK PATENT GmbH (DE) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999055708-A1 | CONDENSED THIENOPYRIMIDINES WITH PHOSPHODIESTERASE-V INHIBITING ACTION | MERCK PATENT GMBH (DE) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | PTGIS, DPYD, PTGIR | ALDH1A1 1785/4885SMN1; SMN2 4332/4885AURKA 1662/4885 |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | EDNRA, EDNRB, PTGIR | ALDH1A1 3483/4885SMN1; SMN2 4122/4885AURKA 1411/4885 |
| US-20040058940-A1 | Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) | PTGER1, PTGIS, PTGIR | ALDH1A1 1756/4885SMN1; SMN2 2595/4885AURKA 2836/4885 |
| US-20030022906-A1 | Use of pde v inhibitors | PDE3A, PDE5A, PDE2A | ALDH1A1 2276/4885SMN1; SMN2 1693/4885AURKA 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.